{
  "name" : "dacemirror.sci-hub.se_journal-article_e04d2ef5572eb435b55af76b5ae59479_luo2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma",
    "authors" : [ "Lijia Luo", "Muhammad Zubair Iqbal", "Chuang Liu", "Jie Xing", "Ozioma Udochukwu Akakuru", "Qianlan Fang", "Zihou Li", "Yunlu Dai", "Aiguo Li", "Yong Guan", "Aiguo Wu" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Contents lists available at ScienceDirect\nBiomaterials\njournal homepage: www.elsevier.com/locate/biomaterials\nEngineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma\nLijia Luoa,b, Muhammad Zubair Iqbala, Chuang Liua,b, Jie Xinga, Ozioma Udochukwu Akakurua,b, Qianlan Fanga,b, Zihou Lia, Yunlu Daic, Aiguo Lid, Yong Guane, Aiguo Wua,∗\na Cixi Institute of Biomedical Engineering, CAS Key Laboratory of Magnetic Materials and Devices, & Key Laboratory of Additive Manufacturing Materials of Zhejiang Province, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, 315201, PR China b Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, PR China c Faculty of Health Sciences, University of Macau, Macau SAR, 999078, PR China d Shanghai Synchrotron Radiation Facility, Chinese Academy of Sciences, Shanghai, 201204, PR China eNational Synchrotron Radiation Laboratory in Hefei, University of Science & Technology of China, Hefei, 230026, PR China\nH I G H L I G H T S\n• Synthesized ultra-small Fe3O4 NPs was found for the first time as nano-immunopotentiators combining with OVA as tumor model antigen, denoted as Fe3O4-OVA nanocomposites. • Fe3O4, as nano-immunopotentiators, could help this nanocomposite Fe3O4-OVA vaccine to efficiently induce the maturation of dendritic cells, activation of macrophages and strongly immune response of T cells. • With the help of Fe3O4 nano-immunopotentiators, this therapeutic Fe3O4-OVA vaccines can efficiently inhibit the subcutaneous and metastatic B16-OVA tumor growth. • This prophylactic Fe3O4-OVA vaccines can successfully prevent the formation of subcutaneous and metastatic tumor in vivo.\nA R T I C L E I N F O\nKeywords: Cancer immunotherapy Nanomaterials Prophylactic vaccines Metastasis Dendritic cells\nA B S T R A C T\nMalignant melanoma, one of the most aggressive types of cancer easily metastasizes, making it extremely difficult to treat and unresponsive to current therapies. Recent breakthroughs in nanomaterials-based cancer immunotherapy have provided potential specific strategy for tumor and metastasis inhibition. With the development of nanotechnology, inorganic nanomaterials have been increasingly studied for their potential cancer therapeutic and molecular imaging functions. However, only iron-based nanomaterials have been approved by the Food and Drug Administration (FDA) in inorganic nanomedicines. For promising clinical application, a new type of nanocomposite is engineered by combining ultra-small iron oxide nanoparticles (Fe3O4 NPs) and ovalbumin (OVA), denoted as Fe3O4-OVA nanocomposites in this study. Interestingly, this is the first time that Fe3O4 NPs are found as nano-immunopotentiators helping nanocomposites efficiently stimulate dendritic cell-based immunotherapy and potentially-activate macrophages. These nanocomposites efficiently stimulate the maturation level of bone marrow derived dendritic cell (BMDCs) and corresponding activation of T cells and also potentially-activate macrophages. With the help of the Fe3O4 nano-immunopotentiators (Fe3O4 NPs), this therapeutic and prophylactic Fe3O4-OVA vaccine can not only efficiently inhibit the subcutaneous and metastatic B16-OVA tumor growth but also successfully prevent the formation of subcutaneous and metastatic tumor, providing a promising strategy for expanding the clinical use of Fe-based nanomaterials."
    }, {
      "heading" : "1. Introduction",
      "text" : "Iron is a type of abundant metallic element in the human body which plays an indispensable role in diverse biological processes such\nas composition of hemoglobin for oxygen transport and storage, and composition of iron enzyme for cellular respiration [1]. With the development of nanotechnology, there arose a crucial need to study nanomaterials used in cancer therapy for their extensive unique\nhttps://doi.org/10.1016/j.biomaterials.2019.119464 Received 12 March 2019; Received in revised form 23 August 2019; Accepted 29 August 2019\n∗ Corresponding author. E-mail address: aiguo@nimte.ac.cn (A. Wu).\nBiomaterials 223 (2019) 119464\nAvailable online 03 September 2019 0142-9612/ © 2019 Elsevier Ltd. All rights reserved.\nT\nadvantages [2,3]. Additionally, corresponding studies on the techniques of nanomaterials have also been well discussed for clinical applications [4,5].\nIn terms of the Food and Drug Administration (FDA)-approved products, nanomaterials with polymers, micelles, liposomes and nanocrystals dominate the available list of such approved nanomedicines [6]. Inorganic nanomaterials with promising therapeutic and imaging functions have been well studied, and many of them are in the clinicaltrials stage [7–11]. Hitherto, only iron-based nanoparticles have been approved by FDA in inorganic nanomedicines, such as ferumoxytol for iron deficiency anemia [6]. Aminosilane-coated superparamagnetic iron oxide nanoparticles (Nanotherm™) received the European Union (EU)-wide regulatory approval for glioblastoma therapy with hyperthermia. Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18]. Based on these various potential functions, IONPs have been studied as agents for multiple tumor therapy [19–22] and combination therapy [23].\nHowever, only a few researches have addressed the promising function of IONPs in cancer immunotherapy. Some groups designed IONPs as nanocarriers to deliver tumor antigens and/or adjuvants for dendritic cell-based cancer immunotherapy [24–28]. Interestingly, Daldrup-Link's group found that the FDA-approved ferumoxytol induced macrophage polarization from anti-inflammatory M2 phenotype to pro-inflammatory M1 phenotype, which could cause the production of reactive oxygen species (ROS) and subcutaneous cancer cell apoptosis through the Fenton reaction of Fe3O4 NPs [29].\nMost researchers studied the biomedical application of iron oxide nanoparticles in cancer immunotherapy mainly taking advantages of MRI or nanocarrier functions of Fe3O4 NPs, but few have focused on their potential positive stimulatory function to the immune system. Malignant melanoma, one of the most aggressive types of cancer, is not common to appear local recurrence, but regional and distant metastasis, particularly in the lung, may arise, which does not respond to current therapies [30]. Many patients suffering from malignant melanoma died from tumor metastasis [31]. Importantly, the treatment and prophylaxis of melanoma metastasis are still the major challenges, hence the development of efficient cancer immunotherapy is desirable [32]. In this study, synthesized ultra-small Fe3O4 NPs was found for the first time as nano-immunopotentiators combining with OVA as tumor model antigen, denoted as Fe3O4-OVA nanocomposites (Fig. 1a). These nanocomposites did not only efficiently stimulate the maturation level of BMDCs and corresponding release of interferon-γ (IFN-γ) from T cells but also potentially activate macrophages with massive release of tumor necrosis factor-α (TNF-α) in vitro. With the help of Fe3O4 nano-immunopotentiators, this therapeutic and prophylactic Fe3O4-OVA vaccines can not only efficiently inhibit the subcutaneous and metastatic B16-OVA tumor growth but also successfully prevent the formation of subcutaneous and metastatic tumor in vivo.\nParticularly, the free Fe3O4 NPs groups demonstrated significant immunotherapeutic ability in these experiments, indicating that the Fe3O4 nano-immunopotentiators not only served as a delivery tool to protect antigens from degradation and inactivation but also participated in cancer immunotherapy as a powerful potentiator to promote immune response, which was uncovered firstly. The effects of Fe3O4OVA vaccines on wild-type B16-F10 tumor were also explored to further indirectly verified their specificity due to dendritic cell-based immunotherapy on B16-OVA tumor."
    }, {
      "heading" : "2. Materials and methods",
      "text" : ""
    }, {
      "heading" : "2.1. Synthesis of Fe3O4",
      "text" : "Ultra-small Fe3O4 nanoparticles were synthesized following our\npreviously-reported procedure with slight modification [33]. Firstly, the iron oleate complex was synthesized by reacting iron chloride and sodium oleate via a modified coprecipitation method. Typically, 2 g of iron oleate complex was dissolved in 20mL of oleyl alcohol and 0.3mL of oleic acid at room temperature, which was degassed with nitrogen flow and refluxed at 300 °C for 60min. The color of the solution changed from brown to black. Then, 50mL of acetone was added to stabilize the nanoparticles after cooling to room temperature. The obtained Fe3O4 nanoparticles were separated by centrifugation and dispersed in cyclohexane. Second, Poly(maleic anhydride-alt-1-octadecene) (PMAO, Mn 30000) and Poly(ethylene glycol) methyl ethers (mPEG-OH, MW 550) were used to synthesize amphiphilic polymers (molar ratio of PMAO:PEG=1:30) by adding several drops of concentrated H2SO4 and refluxing in chloroform at 61 °C for 12 h. The solution was cooled to room temperature, followed by the addition of 1M NaOH to neutralize the H2SO4. After centrifugation, the PMAO-PEG in chloroform was added dropwise into 250mL of diethylether to precipitate polymer which was subsequently filtered, washed with ether and lyophilized. Third, 1 mL of Fe3O4 nanoparticles in cyclohexane was dissolved in 10mL of chloroform, and 2mL of PMAO-PEG (10mg/mL) in chloroform was added in the above solution. The mixture was stirred at room temperature for 12 h. Then 10mL of deionized water was added into the final solution and the chloroform was removed by rotary evaporation. Next, the aqueous dispersed Fe3O4 nanoparticles were obtained for further use."
    }, {
      "heading" : "2.2. Synthesis of Fe3O4-OVA",
      "text" : "Two types of Fe3O4-OVA (Fe-O-1 and Fe-O-2) were obtained after combination of Fe3O4 and OVA with different loading capacities via covalent bonding. In a typical experiment, Fe3O4 solution (1mL, 360 μM for Fe-O-1, 1800 μM for Fe-O-2) was mixed with 1-ethyl-3-(3dimethylaminoropyl) carbodiimide hydrochloride (EDC, 0.5mL, 10mg/mL) in a 10mL reagent bottle, and this mixture was incubated on the rotator at room temperature. After reaction for 2 h, N-hydroxysuccinamide (NHS, 0.5mL, 10mg/mL) and OVA (1mL, 2mg/mL for Fe-O-1, 0.2mg/mL for Fe-O-2) were gently added to the mixture. After 17 h, the unreacted OVA was removed by ultrafiltration (50 k Da, 3500 g) for 1 h under 4 °C. The obtained two types of Fe3O4-OVA were resuspended in PBS for later use."
    }, {
      "heading" : "2.3. Loading capacity measurement",
      "text" : "The loading capacity curves of Fe3O4-OVA were measured by the bicinchoninic acid (BCA) protein assay (Beyotime) according to the manufacturer's instructions. The OVA-loading capacity was calculated as follows: Loading capacity (w/w %) = (weight of OVA/weight of Fe3O4-OVA)× 100."
    }, {
      "heading" : "2.4. Mice and cells",
      "text" : "All animal experimental protocols were approved by Regional Ethics Committee for Animal Experiments at Ningbo University, China. Four-to six-week-old female C57BL/6 mice were purchased from Nanjing Cavins Biotechnology Co., Ltd (Nanjing, China). The macrophage cell line RAW264.7 and B16-F10 melanoma cell line were purchased from the Cell Bank of Shanghai, Chinese Academy of Sciences (Shanghai, China). They were cultured in Dulbecco's modified Eagle's medium (DMEM) with 100 units/mL of penicillin and 100mg/mL of streptomycin (Keygene) supplemented with 10% (v/v) fetal bovine serum (FBS, PAN). OVA-transfected B16 melanoma cell line (B16-OVA) was kindly provided by Prof. Changyang Gong (Sichuan University, China) and was cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (RPMI-1640) with 100 units/mL of penicillin and 100mg/mL of streptomycin (Keygene) supplemented with 10% (v/v) FBS and 800 μg/mL geneticin (Gibco). Bone marrow-derived dendritic\n(caption on next page)\ncells (BMDCs) were prepared according to an established method with a slight modification [34]. Bone marrow cells flushed from the femur and tibia of C57BL/6 mice were collected and red blood cell lysis solution (Solarbio) was used. Cells were cultured in 100mm bacteriological Petri dishes with 5mL RPMI-1640 medium supplemented with 10% (v/ v) fetal bovine serum (FBS), 100 units/mL of penicillin, 100mg/mL of streptomycin, 0.1% (v/v) β-mercaptoethanol (Sigma), 20 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF, PeproTech) and 10 ng/mL interleukin-4 (IL-4, PeproTech). After 3 days, another 5mL of the above-mentioned culture medium was added to each of the Petri dishes. After another 3 days, half of the culture medium was replaced with new medium. After 2 days, immature BMDCs were acquired by centrifuging collected non-adherent and loosely adherent cells in the medium at 1200 rpm for 5min. All the cells were maintained at 37 °C with 5% CO2."
    }, {
      "heading" : "2.5. In vitro biocompatibility",
      "text" : "Cell Counting Kit-8 (CCK-8, MCE) assay was performed to evaluate the in vitro biocompatibility of the Fe3O4 nanoparticles. Briefly, BMDCs (105 cells/well) in 90 μL of complete RPMI-1640 medium were seeded in a 96-well plate, and 10 μL solution of different Fe3O4 nanoparticle concentrations were added to the appropriate wells. After incubation at 37 °C with 5% CO2 for 24 h, 10 μL of CCK-8 solution was added to each well and the plate was incubated for another 2–4 h in the incubator. The absorbance of each well was measured at 450 nm using a microplate reader (iMark 168–1130, Bio-rad)."
    }, {
      "heading" : "2.6. X-ray fluorescence microscopic analysis",
      "text" : "0.5 mL of RAW264.7 cells and immature BMDCs (8× 105 cells/ well) were cultured on a Malay film which was attached to the bottom of a 24-well plate. After 12 h, cells were incubated with 0.5 mL of culture medium, Fe3O4 nanoparticles or Fe-O-2. After another 6 h of incubation, cells were washed with PBS three times, fixed with a 4% formaldehyde solution for 30min and maintained within 1mL PBS. Malay films were washed with deionized water before the elemental fluorescence mappings of the RAW264.7 cells and BMDCs were obtained at hard X-rays BL15U Beamline. This was obtained at the Shanghai Synchrotron Radiation Facility (Shanghai, China) with 10 keV energy of the hard X-ray and 0.5×0.5 μm2 of beam spot."
    }, {
      "heading" : "2.7. 3-D soft X-ray microscopic analysis",
      "text" : "BMDCs (8× 105 cells/well) were cultured with the RPMI-1640 culture medium, Fe3O4 nanoparticles, Fe-O-1 or Fe-O-2 in a 24-well plate at 37 °C with 5% CO2 for 12 h. Suspended cells were collected by centrifugation at 1200 rpm for 5min and were resuspended in 1mL of 4% formaldehyde solution. BMDCs were washed with deionized water 4–6 times before the cell 3-D imaging were obtained on a soft X-rays BL07W Beamline at the National Synchrotron Radiation Facility (Hefei, China)."
    }, {
      "heading" : "2.8. Flow cytometry",
      "text" : "Immature BMDCs (3×105 cells/well) were cultured with the RPMI1640 culture medium, FITC-OVA, FITC-Fe-O-1 or FITC-Fe-O-2 in a 24- well plate at 37 °C with 5% CO2 for 6 h. After removing the culture medium by centrifugation, the FITC fluorescence was measured for the quantitative cellular uptake by flow cytometer (LSRFortessa, BD, USA)."
    }, {
      "heading" : "2.9. Confocal fluorescent microscope imaging",
      "text" : "Immature BMDCs (3×105 cells/well) were seeded in a glass bottom cell culture dish and co-cultured with the RPMI-1640 culture medium, FITC-OVA, FITC-Fe-O-1 or FITC-Fe-O-2 for 6 h. After dyed with LysoTracker®, RAW264.7 cells and immature BMDCs were fixed by paraformaldehyde. Laser confocal imaging was carried out with a confocal laser scanning microscope (TCS SP5 II, Leica). 2.10. DCs maturation.\nImmature BMDCs (5× 105 cells/well) on day 8 were cultured with the RPMI-1640 culture medium, OVA (10 μg/mL), Fe3O4 nanoparticles (90 μM), Fe-O-1 or Fe-O-2 (10 μg/mL of OVA) in a 24-well plate at 37 °C with 5% CO2 for 4 h. Cell suspensions in each well were collected and centrifuged (1200 rpm, 5min) respectively. Cell culture supernatants from different groups were then collected for the ELISA analysis. The secretion of TNF-α was measured by mouse TNF-α ELISA kit (Biolegend) according to the vendor's protocols. Cells from the bottom of the centrifuge tubes were washed with 1% BSA solution and stained with anti-CD11c-PE, anti-CD40− PerCP-eFluor 710 and anti-CD86-FITC (eBioscience) according to vendor's protocols. The population (CD11c+CD40+CD86+) was analyzed for the mature BMDCs by flow cytometer."
    }, {
      "heading" : "2.10. In vitro T cell activation",
      "text" : "Mouse spleen T lymphocytes were obtained from C57BL/6 mice by lymphocyte separation medium (Dakewe). The DCs were treated with OVA (10 μg/mL), Fe3O4 nanoparticles (90 μM), Fe-O-1 or Fe-O-2 (10 μg/mL of OVA) for 4 h. Then, the T cells were co-cultured with the RPMI-1640 medium or the treated DCs at a ratio of 1: 10 for 72 h, respectively. Cell culture supernatants from each group were collected through centrifugation for ELISA analysis. The secretion of IFN-γ was measured by the mouse IFN-γ ELISA kit (Biolegend) according to vendor's protocols."
    }, {
      "heading" : "2.11. RAW264.7 activation",
      "text" : "RAW264.7 cells (5× 105 cells/well) were cultured with the RPMI1640 culture medium, OVA (10 μg/mL), Fe3O4 nanoparticles (90 μM), Fe-O-1 or Fe-O-2 (10 μg/mL of OVA) in a 24-well plate at 37 °C with 5% CO2 for 12 h. Cell culture supernatants in each well were thereafter collected for ELISA analysis. The secretion of TNF-α by RAW264.7 cells was measured by the mouse TNF-α ELISA kit (Biolegend) according to vendor's protocols."
    }, {
      "heading" : "2.12. Ex vivo splenocyte activation",
      "text" : "C57BL/6 female mice were divided into 5 groups (3 mice per group). The mice were subcutaneously immunized with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near the bilateral inguinal lymph nodes (50 μL per side) every 1 week for 3 times. 1 week after the last vaccination, 5×106 spleen cells were obtained from the spleen and retreated with 10 μg/mL OVA for 72 h. Splenocyte activation was characterized by measuring the IFN-γ from spleen cells with ELISA kit."
    }, {
      "heading" : "2.13. Therapeutic vaccines for subcutaneous B16-OVA or wild-type B16-",
      "text" : ""
    }, {
      "heading" : "F10 tumor",
      "text" : "Malignant melanomas were induced in the back (right flank region)\nFig. 1. Characterization and cell uptake analysis of Fe3O4 NPs and Fe3O4-OVA nanocomposites. (a) The schematic illustration on Fe3O4-OVA vaccine strategy. (b) Schematic representation the synthesis of the Fe3O4-OVA vaccine. (c,d) TEM images of (c) Fe3O4 NPs and (d) Fe3O4-OVA nanocomposites. (e) OVA loading capacity curves of Fe3O4-OVA nanocomposites measured by a BCA protein assay. (f,g) XFM images of (f) BMDCs and (g) RAW264.7 cells incubated with PBS, Fe3O4 NPs and Fe3O4-OVA nanocomposites for 6 h by measuring element fluorescence.\nof C57BL/6 female mice by subcutaneous injection of 1× 106 B16-OVA melanoma cells or 8× 105 wild-type B16-F10 melanoma cells. When the tumor size of the subcutaneous melanoma was about 75mm3, the tumor-bearing mice in each type of melanoma were averagely divided into 5 groups (5–6 mice per group). Then the mice were subcutaneously immunized with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near the bilateral inguinal lymph nodes (50 μL per side) every 6 days for 3 times. Subcutaneous tumor size and mice weight were both monitored every 2–3 days. Then, the subcutaneous tumor was cut, and tumor weight was obtained 2–3 days after the last vaccination."
    }, {
      "heading" : "2.14. Prophylactic vaccines for subcutaneous B16-OVA or wild-type B16-",
      "text" : ""
    }, {
      "heading" : "F10 tumor",
      "text" : "C57BL/6 female mice were divided into 10 groups (5–7 mice per group). The mice in every two groups were subcutaneously immunized with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near the left inguinal lymph node and left axillary lymph node (50 μL per side) once a week for 3 times. 6 days after the last vaccination, the mice were subcutaneously injected with 1×106 B16-OVA melanoma cells or 3.5× 105 wild-type B16F10 melanoma cells in the back (right flank region) of the C57BL/6 female mice. When the tumor size of the subcutaneous melanoma in the saline group was about 75mm3, the tumor size and mice weight were both monitored every 2–3 days. The subcutaneous tumor was cut, and tumor weight was obtained 20–22 days after tumor cell injection."
    }, {
      "heading" : "2.15. Therapeutic vaccines for lung metastasis of B16-OVA or B16-OVAluc tumor",
      "text" : "Lung metastasis of melanoma were induced in C57BL/6 female mice by the intravenous injection of 5× 105 B16-OVA melanoma cells or 8× 105 B16-OVA-luc melanoma cells. On day 4, Tumor-bearing mice were randomly divided into 5 groups (5–6 mice per group) and subcutaneously immunized with different vaccines (saline, OVA (200 μg/ mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near the bilateral axillary lymph node (50 μL per side) every 3 days for 3 times. Mice were anesthetized at day 13. Lungs of B16-OVA tumor bearing were removed, the lung metastasis loci were counted and photographed, and the H&E staining of lungs were obtained. B16OVA-luc tumor-bearing mice were intraperitoneally injected with DLuciferin potassium salt (150 mg kg−1), then bioluminescence imaging was performed by IVIS Lumina XRMS Series Ⅲ (PerkinElmer)."
    }, {
      "heading" : "2.16. Prophylactic vaccines for lung metastasis of B16-OVA tumor",
      "text" : "C57BL/6 female mice were divided into 5 groups (5–6 mice per group) and subcutaneously immunized with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near the bilateral axillary lymph node (50 μL per side) every 4 days for 3 times. 4 days after the last vaccination, mice were intravenously injected with 5×105 B16-OVA melanoma cells. Mice were then anesthetized at day 25. Lungs of each group were removed and lung metastasis loci were counted and photographed. Thereafter, the H&E staining of lungs were obtained."
    }, {
      "heading" : "2.17. Statistical analysis",
      "text" : "Data are represented as the mean ± s.e.m. Statistical analysis of data was carried out using one-way ANOVA analysis. A P value of less than 0.05 was considered to be statistically significant."
    }, {
      "heading" : "3. Results and discussion",
      "text" : ""
    }, {
      "heading" : "3.1. Preparation and characterization of Fe3O4 and Fe3O4-OVA",
      "text" : "Fig. 1b demonstrates the detailed synthetic scheme of the Fe3O4OVA vaccine. Fe3O4 nanoparticles were firstly synthesized by the solvothermal method. Transmission electron microscopic (TEM) characterization (Fig. 1c) indicated that the Fe3O4 nanoparticles were uniformly distributed with diameter of 5 nm. Then Fe3O4 nanoparticles were engineered with carboxyl functional groups to be combined with tumor antigen model protein (OVA) through covalent bonding. As shown in Fig. 1d, the TEM image of Fe3O4-OVA nanocomposites indicated that the Fe3O4 nanoparticles have successfully combined with the OVA proteins. The size of the nanocomposite was distributed between 20 and 40 nm. Furthermore, the Energy Dispersive Spectrometer (EDS) mapping of Fe3O4-OVA nanocomposites were performed (Fig. S1). This result further confirmed that the Fe3O4 nanoparticles were successfully combined with the OVA and could act as nano-immunopotentiators to promote subsequent immune response against B16-OVA tumor.\nIn order to investigate the nano-immunopotentiator effect, Fe3O4OVA nanocomposites with different binding rates were synthesized. As shown in Fig. 1e, bicinchoninic acid (BCA) assay was used to measure the concentration-dependent loading capacity curves of the Fe3O4-OVA nanocomposites. Then two kinds of Fe3O4-OVA nanocomposites (donated as Fe-O-1 and Fe-O-2) with different loading capacity were chosen and their abilities to induce different levels of immune responses were investigated. Fe-O-1 nanocomposite refers to Fe3O4-OVA nanocomposite with loading capacity of 97% (w/w) when the weight ratio of OVA/Fe was 100. On the other hand, Fe-O-2 nanocomposite refers to Fe3O4-OVA nanocomposite with loading capacity of 64% (w/w) when the weight ratio of OVA/Fe was 2. And these Fe3O4-OVA nanocomposite were free from endotoxins (Fig. S3).\nThe biocompatibility of the Fe3O4 nanoparticles in vitro was investigated by Cell Counting Kit-8 (CCK-8) assay prior to examining the potential immune-enzyme effects of the Fe3O4-OVA nanocomposites. Bone marrow-derived dendritic cells (BMDCs) were obtained from bone marrow cells of C57BL/6 female mice. After the co-culturing with various concentrations of Fe3O4 nanoparticles from 0 to 1800 μM for 24 h, immature BMDCs presented approximately 80–100% cell viabilities (Fig. S2). These results showed a fairly low cytotoxicity for the Fe3O4 nanoparticles even at a high concentration such as 1800 μM, indicating an appreciable biocompatibility as nano-immunopotentiators for the subsequent experiments."
    }, {
      "heading" : "3.2. Cellular uptake",
      "text" : "BMDCs and macrophages, two of the most important potential professional antigen-presenting cells (APCs), make a significant contribution to recognize, process and present tumor antigen information to T cells in cancer immunotherapy.34,35 Similarly, macrophage activation has a positive effect on adaptive immune response to tumor cells.36 It is necessary to efficiently deliver tumor antigens like OVA into BMDCs and macrophages and effectively stimulate the activation of mature BMDCs from immature BMDCs and the macrophage activation with the help of Fe3O4 nano-immunopotentiators. Therefore, the ability of Fe3O4-OVA nanocomposites to be phagocytized by immature BMDCs and macrophages was investigated. Immature BMDCs and macrophages were co-cultured with PBS, Fe3O4 nano-immunopotentiators and Fe3O4-OVA nanocomposites. Subsequently, Xray fluorescence microscope (XFM) was performed to observe the elemental distribution of both Fe3O4 nano-immunopotentiators and Fe3O4OVA nanocomposites in the immature BMDCs and the macrophages. As shown in the X-ray fluorescence microscopy images (Fig. 1f and g), the element S was used to sketch the cells and the element Fe was used to sketch the nanomaterials. It was obviously observed that the element Fe\naccumulated in the BMDCs and the macrophages incubated with Fe3O4 nano-immunopotentiators and Fe3O4-OVA nanocomposites, while both cells in two control groups did not show any accumulation of the element Fe. These XFM characterization results directly demonstrated that both Fe3O4 nano-immunopotentiators and Fe3O4-OVA nanocomposites could easily penetrate into BMDCs and macrophages.\nFurthermore, the cellular uptake of different nanomaterials was directly observed using a three-dimensional (3-D) soft X-ray microscopy based on free-staining. Videos S1a–d showed the 3-D soft X-ray absorption-contrast imaging of BMDCs incubated with PBS, Fe3O4 nanoimmunopotentiators, Fe-O-1 and Fe-O-2 nanocomposites, respectively, in which the absorptions of soft X-ray by Fe and others in the cell were different. Additionally, high absorption-contrast appeared on the surface of BMDCs or in cells, indicating that Fe existed in the cells. The 3-D soft X-ray microscopic characterization further confirmed that Fe3O4 nano-immunopotentiators and Fe3O4-OVA nanocomposites could be easily phagocytized by BMDCs. Again, it directly demonstrated that the nanomaterials were not just on the surface of BMDCs but truly in the cells to participate in the following immune response experiments.\nSupplementary video related to this article can be found at https:// doi.org/10.1016/j.biomaterials.2019.119464\nThen, the statistical analysis of cellular uptake was characterized using flow cytometry by measuring the mean fluorescence intensity of FITC. In Fig. S4, flow cytometry curves of BMDCs incubated with different groups showed that the fluorescence intensities of FITC in both FITC-Fe-O-1 and FITC-Fe-O-2 nanocomposites groups were significantly stronger than that in free FITC-OVA group, further confirming that OVA could easily be uptaken by BMDCs with the help of Fe3O4 nano-immunopotentiators.\nFor further exploration of cellular uptake, confocal fluorescent microscope imaging was carried out. As shown in Fig. S5, OVA with FITC fluorescent tags have been used in this experiment. It was obviously observed that a little free FITC-OVA were present in the lysosome while FITC-OVA loaded by Fe3O4 nanoparticles mainly co-localized with lysosome after 6 h incubation, suggesting that FITC-OVA were efficiently captured by BMDCs and were present in the lysosome with the help of Fe3O4 nanoparticles."
    }, {
      "heading" : "3.3. Immune response of BMDCs, macrophages and T cells",
      "text" : "Immature BMDCs and macrophages were incubated with different materials (PBS, OVA, Fe3O4, Fe-O-1 and Fe-O-2) in 24-well plates for 4 and 12 h, respectively. After centrifugation, culture supernatants of BMDCs and macrophages were used to measure the secretion of TNF-α by enzyme-linked immunosorbent assay (ELISA). BMDCs were collected to analyze the expression of co-stimulatory molecules (CD40 and CD86) (Fig. 2a). Free Fe3O4 nano-immunopotentiators showed no obvious activation effect on the expression of co-stimulatory molecules from BMDCs compared with the PBS control group. On the other hand, both Fe-O-1 and Fe-O-2 nanocomposites increased the expression of CD11c + CD40 + CD86 + than free OVA did with the same dose of OVA (Fig. 2b). This phenomenon indicated that the Fe3O4 nano-immunopotentiators could promote the immune response of BMDCs to OVA. Notably, it was found that Fe-O-2 could activate BMDCs to express more co-stimulatory molecules than Fe-O-1 could, which proved the effective promotion of the nano-immunopotentiators on immune response. From Fig. 2c, both Fe-O-1 and Fe-O-2 nanocomposites increased more secretion of cytokine TNF-α from DCs than the PBS control group, while Fe-O-2 with more Fe3O4 nano-immunopotentiators significantly increased much more secretion of TNF-α than the free OVA did. This further confirmed that the nano-immunopotentiators played a crucial role in the activation of BMDCs. Furthermore, both FeO-1 and Fe-O-2 nanocomposites increased the secretion of cytokine TNF-α from RAW264.7 macrophages than OVA did, which demonstrated that the Fe3O4 nano-immunopotentiators might have a positive effect on macrophage activation to accelerate tumor immunotherapy\n(Fig. 2d). In this case, it was hypothesized that the efficient process of Fe3O4OVA nanocomposites and maturation of BMDCs would contribute to successful activation of T cells. To verify this hypothesis, T cells were incubated with different types of pulsed BMDCs to test the cytokine IFN-γ secretion from the T cells. In the co-culture supernatants, T cells co-cultured with both Fe3O4-OVA pulsed BMDCs, especially Fe-O-2 pulsed DCs, produced much more cytokine IFN-γ than the free OVA group did (Fig. 2e). This suggested that Fe3O4-OVA pulsed BMDCs, with the help of Fe3O4 nano-immunopotentiators, could efficiently present antigen information to T cells and successfully activate immune response from T cells.\nTo explore whether CDs-OVA can trigger a successful immune response in vivo, ex vivo splenocyte activation was performed before in vivo experiments. C57BL/6 mice were subcutaneously immunized with different vaccines every 1 week for 3 times. 1 week after the last vaccination, spleen cells from different groups were retreated with OVA for 72 h. From the splenocyte activation results (Fig. S6), it was clear that free OVA had a little influence on the expression of IFN-γ from spleen cells while both Fe3O4-OVA nanocomposites exhibited significantly strong splenocyte activation capability, further demonstrating the strong antigen-specific immune response of Fe3O4-OVA nanocomposites with the help of Fe3O4 nano-immunopotentiators.3.4. Therapeutic vaccines for subcutaneous tumor in vivo.\nIn order to determine the ability of Fe3O4 nano-immunopotentiators to make a positive contribution to triggering successful immune response, it would be valuable to further investigate its effect on inhibition of tumor growth in vivo. As shown in the scheme inhibiting subcutaneous B16-OVA tumor (Fig. 3a), C57BL/6 mice were subcutaneously implanted with 1×106 B16-OVA melanoma cells into the back (right flank region). When the tumor volume was about 75mm3, the tumor-bearing mice were subcutaneously immunized with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near bilateral inguinal lymph nodes (50 μL per side) every 6 days for 3 times. The tumor sizes were monitored for 24 days. In Fig. 3b and e, it was found that the free OVA could not inhibit B16-OVA tumor growth in vivo, whereas tumors in both Fe-O-1 and Fe-O-2 groups were suppressed to different degrees, which indicated that Fe3O4 nano-immunopotentiators could protect tumor antigen protein from degradation and inactivation in the complex physiological environment. Particularly, tumor growth inhibition of the Fe-O-2 group was more dramatic than that of the Fe-O-1 group, which indicated that Fe3O4 nano-immunopotentiators could accelerate the antigen process of DCs and activation of T cells in vivo, thereby promoting immune response to OVA-expressed tumor cells (Fig. 3c). Free Fe3O4 nano-immunopotentiators also inhibited tumor growth to a certain degree, because the Fe3O4 induced macrophage activation and subsequent immune response in vivo. The results of tumor weights at day 24 further confirmed the positive effect of Fe3O4 on tumor inhibition (Fig. 3d). During this experiment, mice weights were monitored and there were no weight losses in all groups, suggesting that Fe3O4 nano-immunopotentiators caused no harm to the mice body (Fig. S7). The main organs of the mice from different groups were collected at day 24 and the results of hematoxylin and eosin (H& E)-staining images showed no obvious side effect on the organs, suggesting that the Fe3O4 nano-immunopotentiators and Fe3O4-OVA vaccines also caused no harm to the mice organs (Fig. S8)."
    }, {
      "heading" : "3.4. Prophylactic vaccines for subcutaneous tumor in vivo",
      "text" : "As a successful immune vaccine, it should not only inhibit the existing tumor but also overcome the upcoming tumor challenges. We next sought to prevent subcutaneous B16-OVA tumor formation by pretreatment with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near left inguinal lymph node and left axillary lymph node (50 μL per side)\nonce a week for 3 times (Fig. 3f). After an interval of 1 week, the mice were subcutaneously injected with 1×106 B16-OVA melanoma cells in the back (right flank region) of C57BL/6 female mice. As shown in Fig. 3g, free Fe3O4 nano-immunopotentiators showed no preventive effect on B16-OVA melanoma. The free tumor antigen model OVAtreated mice showed reduced subcutaneous tumor formation to some degree, while both Fe-O-1 and Fe-O-2 nanocomposites-treated mice\nshowed no tumor formation at all. Therefore, the free Fe3O4 nano-immunopotentiators could significantly promote Fe3O4–OVA vaccines to completely prevent tumor formation with no harm to mice body (Fig. 3h). During this experiment, mice weights were monitored and there were no weight losses in all groups, suggesting that Fe3O4 nanoimmunopotentiators caused no harm to the mice body (Fig. 3i).\n(caption on next page)\nFig. 3. Therapeutic and prophylactic vaccines for subcutaneous B16-OVA tumor. (a) The schematic experimental process of subcutaneous B16-OVA tumor inhibition study. (b) Average tumor growth kinetics in control and treated groups for 24 days. (c,d) Individual (c) tumor volume and (d) tumor weight on day 24. (e) Individual tumor growth kinetics for 24 days. Inset: Representative mouse photographs on day 22. Red circles indicate the tumors. (f) The schematic experimental process of subcutaneous B16-OVA tumor prevention study. (g) Average tumor growth kinetics after subcutaneous injection of B16-OVA tumor cells. (h) Individual tumor volume on day 43. (i) Bodyweight changes of mice after different treatments. Data are presented as the mean ± s.e.m. Error bars represent the SD of at least three replicates. Differences among groups are determined using one-way ANOVA analysis. The asterisks indicate the difference between the PBS group and the other groups (*p < 0.05, **p < 0.01); the hashtag symbol indicates that the differences between the groups are statistically significant (#p < 0.5, ##p < 0.01). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)\nFig. 4. Therapeutic vaccines for lung metastasis of B16-OVA and B16-OVA-luc tumor. (a) The schematic experimental process of lung metastasis of B16-OVA or B16OVA-luc tumor inhibition study. (b) In vivo bioluminescence imaging of the B16-OVA-luc lung metastasis in control and treated groups on day 13. (c) Corresponding quantitative lung luminescence of control and treated mice. (d) Representative images of H&E stained lungs from mice intravenously injected with B16-OVA tumor cells and receiving different treatments. Green arrows indicate the tumor areas. The scale bar is 500 μm. Inset: Representative photographs of lungs from each group on day 13. (e) Average and individual lung metastasis loci on day 13. Data are presented as the mean ± s.e.m. Error bars represent the SD of at least three replicates. Differences among groups are determined using one-way ANOVA analysis. The asterisks indicate the difference between the PBS group and the other groups (*p < 0.05, **p < 0.01); the hashtag symbol indicates that the differences between the groups are statistically significant (#p < 0.5, ##p < 0.01). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)"
    }, {
      "heading" : "3.5. Therapeutic vaccines for lung metastasis in vivo",
      "text" : "As it is common to appear distant metastasis in melanoma, particularly in the lung, many patients suffering from malignant melanoma died from tumor metastasis. Therefore, it is necessary to evaluate whether Fe3O4–OVA vaccines have similar therapeutic outcome when the body experiences metastasis. Mice were intravenously injected with 5× 105 B16-OVA or 8×105 B16-OVA-luc melanoma cells to establish lung metastasis models of melanoma. After 4 days, the tumor-bearing mice were subcutaneously immunized with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near bilateral axillary lymph node (50 μL per side) every 3 days for 3 times (Fig. 4a). On day 13, bioluminescence imaging was perform on the B16-OVA-luc tumor-bearing mice, and lungs of B16-OVA tumor-bearing mice were removed then lung metastasis loci were counted and photographed.\nAs shown in Fig. 4b and e, free OVA and Fe3O4–OVA vaccinestreated mice showed inhibited lung metastasis when compared with control group. On day 4 after intravenous injection of B16-OVA tumor cells, even though the immune response caused by free OVA was fairly weak, lung metastasis was not fully established so that there was no big difference of treatment effect between free OVA and Fe-O-1. However, Fe-O-2 vaccine suppressed more lung metastasis than the free OVA did. In accordance with the inhibition of subcutaneous B16-OVA tumor, free Fe3O4 nano-immunopotentiators demonstrated significant ability to inhibit lung metastasis, which might be attributed to its positive effect on macrophage activation.\nMeanwhile, the statistical B16-OVA lung metastasis loci results were consistent with the results of the corresponding quantitative lung luminescence imaging results from B16-OVA-luc tumor, showing that free\nFe3O4 nano-immunopotentiators and Fe3O4–OVA vaccines could efficiently inhibit lung metastasis (Fig. 4c).\nThe H&E-staining images of lungs from each group were shown in Fig. 4d, and red arrows represented lung metastasis areas. These results were similar with those obtained by bioluminescence imaging and counting lung metastasis loci, which further confirmed the inhibited lung metastasis outcome of the Fe3O4–OVA vaccines and the crucial role of the Fe3O4 nano-immunopotentiators in tumor immunotherapy."
    }, {
      "heading" : "3.6. Prophylactic vaccines for lung metastasis in vivo",
      "text" : "As Fe3O4–OVA vaccines showed unexceptionable preventive effects on subcutaneous melanoma, their capacity to prevent lung metastasis was hypothesized. To verify this hypothesis, mice were pretreated with different vaccines (saline, OVA (200 μg/mL), Fe3O4 nanoparticles (1.8 mM), Fe-O-1 or Fe-O-2 (200 μg/mL of OVA)) near the bilateral axillary lymph node (50 μL per side) every 4 days for 3 times. After a 4- day interval, mice were intravenously injected with 5×105 B16-OVA melanoma cells (Fig. 5a). From the results of lung metastasis loci on day 25, Fe-O-1 vaccine-pretreated mice showed almost no metastasis formation. Furthermore, Fe-O-2 vaccine prevented all the mice from lung metastasis, suggesting that the Fe3O4–OVA vaccines could prevent both subcutaneous B16-OVA tumor and B16-OVA lung metastasis (Fig. 5b). As shown in Fig. 5c, the H&E-staining images of lungs indicated that there were many lung metastasis in PBS, OVA and Fe3O4 nano-immunopotentiators groups and very few or no observable lung metastasis in Fe3O4–OVA vaccinated groups. These results were consistent with the statistical results of lung metastasis loci, which further confirmed that the Fe3O4–OVA vaccines aided by the Fe3O4 nano-immunopotentiators could serve as effective prophylactic agents for\nspecifically preventing lung metastasis. To prove the therapeutic and prophylactic specificity of the Fe3O4–OVA vaccines, wild-type B16-F10 tumor model was used with the same routine at the B16-OVA tumor model (Figs. S9 and S6). As shown in Fig. S9 b, c and d, Fe-O-1 vaccine was not able to inhibit wildtype B16-F10 tumor, and Fe-O-2 vaccine showed a little positive inhibitive effect, which might be attributed to the relatively high content of Fe3O4 nano-immunopotentiators in the Fe-O-2 vaccine. As shown in Fig. S10 b, c and d, all the groups demonstrated no preventive effects on wild-type B16-F10 melanoma, which was an indirect proof that Fe3O4–OVA vaccines specifically targeted melanoma expressing OVA tumor antigen."
    }, {
      "heading" : "4. Conclusion",
      "text" : "Through obtained results, it demonstrated that an effective Fe3O4 nano-immunopotentiator to load tumor antigen model OVA for efficient tumor immunotherapy has been developed. These Fe3O4-OVA vaccines were capable of activating mature BMDCs, stimulating T cells and promoting macrophage activation in vitro. Notably, the Fe3O4 nanoimmunopotentiators did not only serve as a delivery tool for protecting antigens from degradation and inactivation in the complex physiological environment but also function as an activator to promote immunotherapy at a low dosage. The therapeutic and prophylactic effects of Fe3O4-OVA vaccines on subcutaneous or metastatic tumor growth and formation were substantiated due to dendritic cell-based immunotherapy with potential macrophage activation. Altogether, these detailed results have crucial implications on expanding the biological applications of Fe3O4 nano-immunopotentiators and the discovery of more extraordinary performances of same for cancer immunotherapy."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The authors express their appreciation on the unyielding support from Rui Shu from Linköping University. And the authors are also grateful to Professor Changyang Gong from Sichuan University and Zhe Yu from Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences. This work was supported by National Key R&D Program of China (2018YFC0910601), Natural Science Foundation of China (31971292 and U1432114 to Aiguo Wu), Zhejiang Province Financial Supporting (2017C03042, LY18H180011), The Science & Technology Bureau of Ningbo City (2015B11002, 2017C110022). Furthermore, the authors also acknowledge Shanghai Synchrotron Radiation Facility at Line BL15U (No. h15sr0021) used for X-ray fluorescence imaging and National Synchrotron Radiation Laboratory in Hefei used for soft X-ray imaging (No. 2016-HLS-PT002193)."
    }, {
      "heading" : "Appendix A. Supplementary data",
      "text" : "Supplementary data to this article can be found online at https:// doi.org/10.1016/j.biomaterials.2019.119464."
    } ],
    "references" : [ {
      "title" : "Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents",
      "author" : [ "N. Lee", "T. Hyeon" ],
      "venue" : "Chem. Soc. Rev. 41 (7) ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Nanomaterials for theranostics: recent advances and future challenges",
      "author" : [ "E.K. Lim", "T. Kim", "S. Paik", "S. Haam", "Y.M. Huh", "K. Lee" ],
      "venue" : "Chem. Rev. 115 (1) ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nanomaterial-based cancer immunotherapy",
      "author" : [ "L. Luo", "R. Shu", "A. Wu" ],
      "venue" : "J. Mater. Chem. B 5 (28) ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Understanding biophysicochemical interactions at the nano-bio interface",
      "author" : [ "A.E. Nel", "L. Madler", "D. Velegol", "T. Xia", "E.M. Hoek", "P. Somasundaran", "F. Klaessig", "V. Castranova", "M. Thompson" ],
      "venue" : "Nat. Mater. 8 (7) ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Principles of nanoparticle design for overcoming biological barriers to drug delivery",
      "author" : [ "E. Blanco", "H. Shen", "M. Ferrari" ],
      "venue" : "Nat. Biotechnol. 33 (9) ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date",
      "author" : [ "D. Bobo", "K.J. Robinson", "J. Islam", "K.J. Thurecht", "S.R. Corrie" ],
      "venue" : "Pharm. Res. 33 (10) ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe",
      "author" : [ "E. Phillips", "O. Penate-Medina", "P.B. Zanzonico", "R.D. Carvajal", "P. Mohan", "Y. Ye", "J. Humm", "M. Gonen", "H. Kalaigian", "H. Schoder", "H.W. Strauss", "S.M. Larson", "U. Wiesner", "M.S. Bradbury" ],
      "venue" : "Sci. Transl. Med. 6 (260) ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial",
      "author" : [ "A.N. Kharlamov", "A.E. Tyurnina", "V.S. Veselova", "O.P. Kovtun", "V.Y. Shur", "J.L. Gabinsky" ],
      "venue" : "Nanoscale 7 (17) ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "A",
      "author" : [ "P. Pedrosa", "R. Vinhas" ],
      "venue" : "Fernandes, P.V. Baptista, Gold nanotheranostics: proof-of-concept or clinical tool? Nanomaterials 5 (4) ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches",
      "author" : [ "K. Ulbrich", "K. Hola", "V. Subr", "A. Bakandritsos", "J. Tucek", "R. Zboril" ],
      "venue" : "release control, and clinical studies, Chem. Rev. 116 (9) ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Emerging strategies of cancer therapy based on ferroptosis",
      "author" : [ "Z. Shen", "J. Song", "B.C. Yung", "Z. Zhou", "A. Wu", "X. Chen" ],
      "venue" : "Adv. Mater. 30 (12) ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Tumor-selective catalytic nanomedicine by nanocatalyst delivery",
      "author" : [ "M. Huo", "L. Wang", "Y. Chen", "J. Shi" ],
      "venue" : "Nat. Commun. 8 (1) ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Ultrasound-induced reactive oxygen species mediated therapy and imaging using a Fenton reaction activable polymersome",
      "author" : [ "W.P. Li", "C.H. Su", "Y.C. Chang", "Y.J. Lin", "C.S. Yeh" ],
      "venue" : "ACS Nano 10 (2) ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Enhanced NIR radiation-triggered hyperthermia by mitochondrial targeting",
      "author" : [ "H.S. Jung", "J. Han", "J.H. Lee", "J.H. Lee", "J.M. Choi", "H.S. Kweon", "J.H. Han", "J.H. Kim", "K.M. Byun", "J.H. Jung", "C. Kang", "J.S. Kim" ],
      "venue" : "J. Am. Chem. Soc. 137 (8) ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Magnetic targeting enhanced theranostic strategy based on multimodal imaging for selective ablation of cancer",
      "author" : [ "Z. Li", "S. Yin", "L. Cheng", "K. Yang", "Y. Li", "Z. Liu" ],
      "venue" : "Adv. Funct. Mater. 24 (16) ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Large-scale synthesis of colloidal Fe3O4 nanoparticles exhibiting high heating efficiency in magnetic hyperthermia",
      "author" : [ "Y.V. Kolen’ko", "M. Bañobre-López", "C. Rodríguez-Abreu", "E. Carbó-Argibay", "A. Sailsman", "Y. Piñeiro-Redondo", "M.F. Cerqueira", "D.Y. Petrovykh", "K. Kovnir", "O.I. Lebedev", "J. Rivas" ],
      "venue" : "J. Phys. Chem. C",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2014
    }, {
      "title" : "Orientation mediated enhancement on magnetic hyperthermia of  Fe3O4 nanodisc",
      "author" : [ "Y. Yang", "X. Liu", "Y. Lv", "T.S. Herng", "X. Xu", "W. Xia", "T. Zhang", "J. Fang", "W. Xiao", "J. Ding" ],
      "venue" : "Adv. Funct. Mater. 25 (5) ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Fentonreaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors",
      "author" : [ "Z. Shen", "T. Liu", "Y. Li", "J. Lau", "Z. Yang", "W. Fan", "Z. Zhou", "C. Shi", "C. Ke", "V.I. Bregadze", "S.K. Mandal", "Y. Liu", "Z. Li", "T. Xue", "G. Zhu", "J. Munasinghe", "G. Niu", "A. Wu", "X. Chen" ],
      "venue" : "ACS Nano 12 (11) ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Multiple hyperthermia-mediated release of TRAIL/SPION nanocomplex from thermosensitive polymeric hydrogels for combination cancer therapy",
      "author" : [ "Z.Q. Zhang", "S.C. Song" ],
      "venue" : "Biomaterials 132 ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Antitumor platelet-mimicking magnetic nanoparticles",
      "author" : [ "L. Rao", "L.-L. Bu", "Q.-F. Meng", "B. Cai", "W.-W. Deng", "A. Li", "K. Li", "S.-S. Guo", "W.-F. Zhang", "W. Liu", "Z.-J. Sun", "X.-Z. Zhao" ],
      "venue" : "Adv. Funct. Mater. 27 (9) ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Therapeutic applications of iron oxide based nanoparticles in cancer: basic concepts and recent advances",
      "author" : [ "M. Saeed", "W. Ren", "A. Wu" ],
      "venue" : "Biomater. Sci. 6 (4) ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Duality of iron oxide nanoparticles in cancer therapy: amplification of heating efficiency by magnetic hyperthermia and photothermal bimodal treatment",
      "author" : [ "A. Espinosa", "R. Di Corato", "J. Kolosnjaj-Tabi", "P. Flaud", "T. Pellegrino", "C. Wilhelm" ],
      "venue" : "ACS Nano 10 (2) ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy",
      "author" : [ "N.H. Cho", "T.C. Cheong", "J.H. Min", "J.H. Wu", "S.J. Lee", "D. Kim", "J.S. Yang", "S. Kim", "Y.K. Kim", "S.Y. Seong" ],
      "venue" : "Nat. Nanotechnol. 6 (10) ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Microdosed lipid-coated (67)Ga-magnetite enhances antigen-specific immunity by image tracked delivery of antigen and CpG to lymph nodes",
      "author" : [ "A. Ruiz-de-Angulo", "A. Zabaleta", "V. Gomez-Vallejo", "J. Llop", "J.C. Mareque-Rivas" ],
      "venue" : "ACS Nano 10 (1) ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Iron oxide nanoparticles-based vaccine delivery for cancer treatment",
      "author" : [ "Y. Zhao", "X. Zhao", "Y. Cheng", "X. Guo", "W. Yuan" ],
      "venue" : "Mol. Pharm. 15 (5) ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "The induction of maturation on dendritic cells by TiO2 and Fe(3)O(4)@TiO(2) nanoparticles via NF-kappaB signaling pathway",
      "author" : [ "R. Zhu", "Y. Zhu", "M. Zhang", "Y. Xiao", "X. Du", "H. Liu", "S. Wang" ],
      "venue" : "Mater. Sci. Eng. C Mater. Biol. Appl. 39 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Personalized cancer immunotherapy via transporting endogenous tumor antigens to lymph nodes mediated by nano Fe3 O4",
      "author" : [ "B. Wang", "J. An", "H. Zhang", "S. Zhang", "H. Zhang", "L. Wang", "H. Zhang", "Z. Zhang" ],
      "venue" : "Small 14 (38) ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues",
      "author" : [ "S. Zanganeh", "G. Hutter", "R. Spitler", "O. Lenkov", "M. Mahmoudi", "A. Shaw", "J.S. Pajarinen", "H. Nejadnik", "S. Goodman", "M. Moseley", "L.M. Coussens", "H.E. Daldrup-Link" ],
      "venue" : "Nat. Nanotechnol. 11 (11) ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Melanoma biology and new targeted therapy",
      "author" : [ "V. Gray-Schopfer", "C. Wellbrock", "R. Marais" ],
      "venue" : "Nature 445 (7130) ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Biology of melanoma metastasis",
      "author" : [ "M. Qiaoli", "C.D. Lothar", "D. Michael" ],
      "venue" : "in: D.E. Fisher, B.C. Bastian (Eds.), Melanoma, Springer, New York",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy",
      "author" : [ "D.W. Zheng", "J.L. Chen", "J.Y. Zhu", "L. Rong", "B. Li", "Q. Lei", "J.X. Fan", "M.Z. Zou", "C. Li", "S.X. Cheng", "Z. Xu", "X.Z. Zhang" ],
      "venue" : "Nano Lett. 16 (7) ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "T",
      "author" : [ "M.Z. Iqbal", "X. Ma" ],
      "venue" : "Chen, L.e. Zhang, W. Ren, L. Xiang, A. Wu, Silica-coated superparamagnetic iron oxide nanoparticles (SPIONPs): a new type contrast agent of T1 magnetic resonance imaging (MRI), J. Mater. Chem. B 3 (26) ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow",
      "author" : [ "M.B. Lutz", "N. Kukutsch", "A.L.J. Ogilvie", "S. Rossner", "F. Koch", "N. Romani", "G. Schuler" ],
      "venue" : "J. Immunol. Methods 223 (1) (1999) 77–92.  L. Luo, et al. Biomaterials 223 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2019
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Iron is a type of abundant metallic element in the human body which plays an indispensable role in diverse biological processes such as composition of hemoglobin for oxygen transport and storage, and composition of iron enzyme for cellular respiration [1].",
      "startOffset" : 252,
      "endOffset" : 255
    }, {
      "referenceID" : 3,
      "context" : "Additionally, corresponding studies on the techniques of nanomaterials have also been well discussed for clinical applications [4,5].",
      "startOffset" : 127,
      "endOffset" : 132
    }, {
      "referenceID" : 4,
      "context" : "Additionally, corresponding studies on the techniques of nanomaterials have also been well discussed for clinical applications [4,5].",
      "startOffset" : 127,
      "endOffset" : 132
    }, {
      "referenceID" : 5,
      "context" : "In terms of the Food and Drug Administration (FDA)-approved products, nanomaterials with polymers, micelles, liposomes and nanocrystals dominate the available list of such approved nanomedicines [6].",
      "startOffset" : 195,
      "endOffset" : 198
    }, {
      "referenceID" : 5,
      "context" : "Hitherto, only iron-based nanoparticles have been approved by FDA in inorganic nanomedicines, such as ferumoxytol for iron deficiency anemia [6].",
      "startOffset" : 141,
      "endOffset" : 144
    }, {
      "referenceID" : 10,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 204,
      "endOffset" : 208
    }, {
      "referenceID" : 11,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 228,
      "endOffset" : 235
    }, {
      "referenceID" : 12,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 228,
      "endOffset" : 235
    }, {
      "referenceID" : 13,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 258,
      "endOffset" : 265
    }, {
      "referenceID" : 14,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 258,
      "endOffset" : 265
    }, {
      "referenceID" : 15,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 293,
      "endOffset" : 300
    }, {
      "referenceID" : 16,
      "context" : "Hence, there is no doubt that iron oxide nanoparticles (IONPs) have attracted extensive attention owing to their wide biomedical applications, such as contrast agents for magnetic resonance imaging (MRI) [12], tumor ferroptosis [13,14], photothermal therapy [15,16], and magnetic hyperthermia [17,18].",
      "startOffset" : 293,
      "endOffset" : 300
    }, {
      "referenceID" : 21,
      "context" : "Based on these various potential functions, IONPs have been studied as agents for multiple tumor therapy [19–22] and combination therapy [23].",
      "startOffset" : 137,
      "endOffset" : 141
    }, {
      "referenceID" : 27,
      "context" : "Interestingly, Daldrup-Link's group found that the FDA-approved ferumoxytol induced macrophage polarization from anti-inflammatory M2 phenotype to pro-inflammatory M1 phenotype, which could cause the production of reactive oxygen species (ROS) and subcutaneous cancer cell apoptosis through the Fenton reaction of Fe3O4 NPs [29].",
      "startOffset" : 324,
      "endOffset" : 328
    }, {
      "referenceID" : 28,
      "context" : "Malignant melanoma, one of the most aggressive types of cancer, is not common to appear local recurrence, but regional and distant metastasis, particularly in the lung, may arise, which does not respond to current therapies [30].",
      "startOffset" : 224,
      "endOffset" : 228
    }, {
      "referenceID" : 29,
      "context" : "Many patients suffering from malignant melanoma died from tumor metastasis [31].",
      "startOffset" : 75,
      "endOffset" : 79
    }, {
      "referenceID" : 30,
      "context" : "Importantly, the treatment and prophylaxis of melanoma metastasis are still the major challenges, hence the development of efficient cancer immunotherapy is desirable [32].",
      "startOffset" : 167,
      "endOffset" : 171
    }, {
      "referenceID" : 31,
      "context" : "Ultra-small Fe3O4 nanoparticles were synthesized following our previously-reported procedure with slight modification [33].",
      "startOffset" : 118,
      "endOffset" : 122
    }, {
      "referenceID" : 32,
      "context" : "cells (BMDCs) were prepared according to an established method with a slight modification [34].",
      "startOffset" : 90,
      "endOffset" : 94
    } ],
    "year" : 2019,
    "abstractText" : "Malignant melanoma, one of the most aggressive types of cancer easily metastasizes, making it extremely difficult to treat and unresponsive to current therapies. Recent breakthroughs in nanomaterials-based cancer immunotherapy have provided potential specific strategy for tumor and metastasis inhibition. With the development of nanotechnology, inorganic nanomaterials have been increasingly studied for their potential cancer therapeutic and molecular imaging functions. However, only iron-based nanomaterials have been approved by the Food and Drug Administration (FDA) in inorganic nanomedicines. For promising clinical application, a new type of nanocomposite is engineered by combining ultra-small iron oxide nanoparticles (Fe3O4 NPs) and ovalbumin (OVA), denoted as Fe3O4-OVA nanocomposites in this study. Interestingly, this is the first time that Fe3O4 NPs are found as nano-immunopotentiators helping nanocomposites efficiently stimulate dendritic cell-based immunotherapy and potentially-activate macrophages. These nanocomposites efficiently stimulate the maturation level of bone marrow derived dendritic cell (BMDCs) and corresponding activation of T cells and also potentially-activate macrophages. With the help of the Fe3O4 nano-immunopotentiators (Fe3O4 NPs), this therapeutic and prophylactic Fe3O4-OVA vaccine can not only efficiently inhibit the subcutaneous and metastatic B16-OVA tumor growth but also successfully prevent the formation of subcutaneous and metastatic tumor, providing a promising strategy for expanding the clinical use of Fe-based nanomaterials.",
    "creator" : "Elsevier"
  }
}